THE EFFECT OF INCREASING THE TREATMENT TIME BEYOND 3 WEEKS ON THE CONTROL OF T2 AND T3 LARYNGEAL-CANCER USING RADIOTHERAPY

被引:86
作者
SLEVIN, NJ
HENDRY, JH
ROBERTS, SA
AGRENCRONQVIST, A
机构
[1] CHRISTIE HOSP & HOLT RADIUM INST,CANC RES CAMPAIGN,DEPT RADIOTHERAPY,MANCHESTER M20 9BX,LANCS,ENGLAND
[2] CHRISTIE HOSP TRUST,NATL HLTH SERV,DEPT EXPTL RADIAT ONCOL,MANCHESTER M20 9BX,ENGLAND
[3] CHRISTIE HOSP,NATL HLTH SERV,PATERSON INST CANC RES,DEPT BIOMATH & COMP,MANCHESTER M20 9BX,ENGLAND
关键词
TREATMENT TIME; T2 AND T3; CONTROL OF LARYNGEAL CANCER;
D O I
10.1016/0167-8140(92)90226-K
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Local control of cancer by radiotherapy may be prejudiced by accelerated tumour clonogen repopulation particularly during protracted treatment schedules. A series of 496 cases of T2 and T3 larynx cancer treated here by radiotherapy has been studied to examine the impact on local control of treatment durations ranging from 9 to 41 days. Data were analysed using a linear-quadratic formulation describing the fractionation sensitivity, with the incorporation of a parameter relating to treatment time. Using combined T2 and T3 data, the increase in dose required to maintain a constant local control (the time factor) was between 0.5 and 0.6 Gy per day. These values are similar to those reported for 4 weeks or more in the literature. Also, the calculated dose to control 50% of tumours, given over the standard Christie duration of 21 days, was on the line projected back from literature data over 28-66 days. The present data are consistent with the presence of such a time factor following a lag phase of not more than 3 weeks after starting radiotherapy. Hence, further consideration should be given to using shorter overall treatment times in radiotherapy for head and neck cancer.
引用
收藏
页码:215 / 220
页数:6
相关论文
共 17 条
[1]   NEW OPTIONS IN DIRECT ANALYSIS OF DOSE-RESPONSE DATA [J].
BENTZEN, SM ;
THAMES, HD ;
TUCKER, SL ;
SMITH, C .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1990, 57 (01) :221-225
[2]   CLINICAL RADIOBIOLOGY OF SQUAMOUS-CELL CARCINOMA OF THE OROPHARYNX [J].
BENTZEN, SM ;
JOHANSEN, LV ;
OVERGAARD, J ;
THAMES, HD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 20 (06) :1197-1206
[3]   CLINICAL-EVIDENCE FOR TUMOR CLONOGEN REGENERATION - INTERPRETATIONS OF THE DATA [J].
BENTZEN, SM ;
THAMES, HD .
RADIOTHERAPY AND ONCOLOGY, 1991, 22 (03) :161-166
[4]  
BUDIHNA M, 1980, STRAHLENTHER ONKOL, V156, P402
[5]   CONTINUOUS, HYPERFRACTIONATED, ACCELERATED RADIOTHERAPY (CHART) [J].
DISCHE, S ;
SAUNDERS, MI .
BRITISH JOURNAL OF CANCER, 1989, 59 (03) :325-326
[6]   DOSE FRACTIONATION AND REGENERATION IN RADIOTHERAPY FOR CANCER OF THE ORAL CAVITY AND OROPHARYNX - TUMOR DOSE-RESPONSE AND REPOPULATION [J].
MACIEJEWSKI, B ;
WITHERS, HR ;
TAYLOR, JMG ;
HLINIAK, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 16 (03) :831-843
[7]   THE INFLUENCE OF THE NUMBER OF FRACTIONS AND OF OVERALL TREATMENT TIME ON LOCAL-CONTROL AND LATE COMPLICATION RATE IN SQUAMOUS-CELL CARCINOMA OF THE LARYNX [J].
MACIEJEWSKI, B ;
PREUSSBAYER, G ;
TROTT, KR .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1983, 9 (03) :321-328
[8]   COMPARISON OF CONVENTIONAL AND SPLIT-COURSE RADIOTHERAPY AS PRIMARY-TREATMENT IN CARCINOMA OF THE LARYNX [J].
OVERGAARD, J ;
HJELMHANSEN, M ;
JOHANSEN, LV ;
ANDERSEN, AP .
ACTA ONCOLOGICA, 1988, 27 (02) :147-152
[9]  
SLEVIN NJ, 1992, IN PRESS INT J RAD O
[10]   STEEPNESS OF DOSE-RESPONSE CURVE BOTH FOR TUMOR CURE AND NORMAL TISSUE INJURY [J].
STEWART, JG ;
JACKSON, AW .
LARYNGOSCOPE, 1975, 85 (07) :1107-1111